Key facts
- Ampersand Biomedicines’s last known valuation is $338.0M (Mar 2025).
- It has raised $115.0M; the latest was Early Stage VC ($65.0M) in Mar 2025.
- Notable investors include Flagship Pioneering, Eli Lilly.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ampersand Biomedicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Ampersand Biomedicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ampersand Biomedicines
Developer of medicines and body therapeutics designed to act at the site of disease. The company combines a localizing element that enables disease-specific precision with an actuator specifically chosen for disease modification, enabling researchers to navigate a large range of diseases in almost all areas of the body.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 45
- Website
- ampersand.bio/
- Ownership
- Privately Held (backing)
Ampersand Biomedicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ampersand Biomedicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ampersand Biomedicines in its N-PORT filings yet. We sweep new filings monthly.